Cargando…
Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion
Sickle cell disease patients are commonly treated at transfusion medicine services, and understanding of the hepatic manifestations of the disease is key for optimal management, specifically, in individuals presenting with sickle cell intrahepatic cholestasis (SCIC). SCIC represents a rare, severe h...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Atlantis Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432363/ https://www.ncbi.nlm.nih.gov/pubmed/34595422 http://dx.doi.org/10.2991/chi.d.190630.001 |
_version_ | 1783751145141829632 |
---|---|
author | Adkins, Brian D. Savani, Bipin N. Booth, Garrett S. |
author_facet | Adkins, Brian D. Savani, Bipin N. Booth, Garrett S. |
author_sort | Adkins, Brian D. |
collection | PubMed |
description | Sickle cell disease patients are commonly treated at transfusion medicine services, and understanding of the hepatic manifestations of the disease is key for optimal management, specifically, in individuals presenting with sickle cell intrahepatic cholestasis (SCIC). SCIC represents a rare, severe hepatic crisis wherein sinusoidal red cell sickling leads to massive hepatocyte dysfunction and cholestatic laboratory findings. Acute SCIC is defined by abdominal pain with progressive hepatic injury associated with hyperbilirubinemia, renal failure, encephalopathy, and coagulopathy. Patients are generally managed with red blood cell exchange transfusion (RBCEx), when available, as this is a potentially fatal condition. Simple transfusion may be utilized in resource-poor environment or when patients refuse RBCEx. As less than 50 adult cases have been described in the literature, many of them with limited follow-up, randomized clinical trials comparing RBCEx with other treatments are currently unfeasible. Likewise, a chronic form exists, but is less well characterized, and is associated with persistent bilirubinemia and a variable course in terms of progressive hepatic disease. We undertake a brief review of the literature and discuss two cases of SCIC managed with RBCEx at our institution. |
format | Online Article Text |
id | pubmed-8432363 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Atlantis Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-84323632021-09-29 Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion Adkins, Brian D. Savani, Bipin N. Booth, Garrett S. Clin Hematol Int Perspective Sickle cell disease patients are commonly treated at transfusion medicine services, and understanding of the hepatic manifestations of the disease is key for optimal management, specifically, in individuals presenting with sickle cell intrahepatic cholestasis (SCIC). SCIC represents a rare, severe hepatic crisis wherein sinusoidal red cell sickling leads to massive hepatocyte dysfunction and cholestatic laboratory findings. Acute SCIC is defined by abdominal pain with progressive hepatic injury associated with hyperbilirubinemia, renal failure, encephalopathy, and coagulopathy. Patients are generally managed with red blood cell exchange transfusion (RBCEx), when available, as this is a potentially fatal condition. Simple transfusion may be utilized in resource-poor environment or when patients refuse RBCEx. As less than 50 adult cases have been described in the literature, many of them with limited follow-up, randomized clinical trials comparing RBCEx with other treatments are currently unfeasible. Likewise, a chronic form exists, but is less well characterized, and is associated with persistent bilirubinemia and a variable course in terms of progressive hepatic disease. We undertake a brief review of the literature and discuss two cases of SCIC managed with RBCEx at our institution. Atlantis Press 2019-09-01 /pmc/articles/PMC8432363/ /pubmed/34595422 http://dx.doi.org/10.2991/chi.d.190630.001 Text en © 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ). |
spellingShingle | Perspective Adkins, Brian D. Savani, Bipin N. Booth, Garrett S. Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion |
title | Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion |
title_full | Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion |
title_fullStr | Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion |
title_full_unstemmed | Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion |
title_short | Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion |
title_sort | management of sickle cell intrahepatic cholestasis: an argument in favor of automated exchange transfusion |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432363/ https://www.ncbi.nlm.nih.gov/pubmed/34595422 http://dx.doi.org/10.2991/chi.d.190630.001 |
work_keys_str_mv | AT adkinsbriand managementofsicklecellintrahepaticcholestasisanargumentinfavorofautomatedexchangetransfusion AT savanibipinn managementofsicklecellintrahepaticcholestasisanargumentinfavorofautomatedexchangetransfusion AT boothgarretts managementofsicklecellintrahepaticcholestasisanargumentinfavorofautomatedexchangetransfusion |